Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
GAITHERSBURG, Md., April 25, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse® Knowledgebase to predict antibiotic susceptibility. The results were presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.
The poster, titled “Prediction of antibiotic resistance in Escherichia coli from resistance genes,” compared phenotypic antibiotic susceptibility testing (AST) with the emerging capabilities of Lighthouse Knowledgebase informatics to predict antibiotic resistance using resistance genes from bacterial isolates. The results of testing over 1,900 E. coli isolates with PCR yielded strong prediction of phenotypic antibiotic resistance for seventeen antibiotics representing seven antibiotic classes with accuracies ranging from 77% to 97%. Resistance for 12 of the antibiotics were predicted with 90% or greater accuracy.
A second poster, titled “Rapid outbreak detection of multidrug-resistant organisms using resistance gene profiles,” illustrated the potential to detect hospital pathogen outbreaks by clustering isolates based on resistance gene profiles using a PCR-based test. Outbreak clusters of P. aeruginosa and E. coli were accurately discriminated using multiple resistance genes, thereby demonstrating that a multiplexed PCR-based test has potential to be a rapid, accurate, and efficient method for surveillance of multidrug-resistant organisms.
“In the preliminary results presented at ECCMID, our Acuitas technology demonstrated the ability to rapidly and accurately predict antibiotic susceptibility using resistance gene profiles,” said Evan Jones, Chairman and CEO of OpGen. “The development of our first Acuitas Rapid Test to detect resistance genes for interpretation by our Acuitas Lighthouse informatics is underway. The data presented at ECCMID support the potential clinical utility of this exciting new technology.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
